English
Insider transactions
EDGARARMATA PHARMACEUTICALS, INC.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-17.
- Open-market purchases (code P)
- 0 transactions, — shares
- Open-market sales (code S)
- 0 transactions, — shares
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–13 of 13
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-10 Filed 2026-07-14 | Birx Deborah Director · Officer: Chief Executive Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 14,041 | 4.26 | 59,814.66Derived: shares × price per share. Exact value 59814.66. | 198,417 | Direct (D) | No | F1
| Open filing 0001104659-26-083516 Read from the filing’s XML Dispute this row |
| 2026-04-24 Filed 2026-04-28 | Gilmer Daniel B. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 51,280 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 51,280 | Direct (D) | No | F1
| Open filing 0001104659-26-050391 Read from the filing’s XML Dispute this row |
| 2026-03-14 Filed 2026-03-17 | Kyme Pierre Officer: Chief Business Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 1,030 | 10.54 | 10,856.2Derived: shares × price per share. Exact value 10856.20. | 9,461 | Direct (D) | No | F1
| Open filing 0001104659-26-029712 Read from the filing’s XML Dispute this row |
| 2026-03-14 Filed 2026-03-17 | Birx Deborah Director · Officer: Chief Executive Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 4,919 | 10.54 | 51,846.26Derived: shares × price per share. Exact value 51846.26. | 212,458 | Direct (D) | No | F1
| Open filing 0001104659-26-029711 Read from the filing’s XML Dispute this row |
| 2026-03-09 Filed 2026-03-11 | House David Duane Officer: SVP, Finance, and PFO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 109,885 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 109,885 | Direct (D) | No | F1
| Open filing 0001104659-26-026587 Read from the filing’s XML Dispute this row |
| 2026-03-09 Filed 2026-03-11 | Schlesinger Sarah J. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,640 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 25,640 | Direct (D) | No | F1
| Open filing 0001104659-26-026581 Read from the filing’s XML Dispute this row |
| 2026-03-09 Filed 2026-03-11 | Odysseas Kostas D Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,640 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 25,640 | Direct (D) | No | F1
| Open filing 0001104659-26-026583 Read from the filing’s XML Dispute this row |
| 2026-03-09 Filed 2026-03-11 | Kramer Robin Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,640 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 25,640 | Direct (D) | No | F1
| Open filing 0001104659-26-026589 Read from the filing’s XML Dispute this row |
| 2026-03-09 Filed 2026-03-11 | Haimovitz Jules Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,640 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 25,640 | Direct (D) | No | F1
| Open filing 0001104659-26-026579 Read from the filing’s XML Dispute this row |
| 2026-03-09 Filed 2026-03-11 | Peterson Todd C. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,640 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 25,640 | Direct (D) | No | F1
| Open filing 0001104659-26-026585 Read from the filing’s XML Dispute this row |
| 2026-03-09 Filed 2026-03-11 | PATTI JOSEPH M Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,640 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 25,640 | Direct (D) | No | F1
| Open filing 0001104659-26-026586 Read from the filing’s XML Dispute this row |
| 2026-03-09 Filed 2026-03-11 | Kyme Pierre Officer: Chief Business Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 183,142 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 183,142 | Direct (D) | No | F1
| Open filing 0001104659-26-026588 Read from the filing’s XML Dispute this row |
| 2026-03-09 Filed 2026-03-11 | Birx Deborah Director · Officer: Chief Executive Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 421,226 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 421,226 | Direct (D) | No | F1
| Open filing 0001104659-26-026582 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| Innoviva, Inc. Common Stock, $0.01 par value | 82.7 | 55,467,459.00 | 05/12/2026 Filed 2026-05-13 | SCHEDULE 13D/AAmendment 15 | Open filing 0001104659-26-060384 Dispute this row |
| Innoviva Strategic Opportunities LLC Common Stock, $0.01 par value | 69.7 | 46,756,659.00 | 05/12/2026 Filed 2026-05-13 | SCHEDULE 13D/AAmendment 15 | Open filing 0001104659-26-060384 Dispute this row |
| Innoviva, Inc. Common Stock, $0.01 par value | 83.1 | 55,467,459.00 | 01/23/2026 Filed 2026-01-26 | SCHEDULE 13D/AAmendment 14 | Open filing 0001140361-26-002376 Dispute this row |
| Innoviva Strategic Opportunities LLC Common Stock, $0.01 par value | 70.1 | 46,756,659.00 | 01/23/2026 Filed 2026-01-26 | SCHEDULE 13D/AAmendment 14 | Open filing 0001140361-26-002376 Dispute this row |
| Innoviva, Inc. Common Stock, $0.01 par value | 83.3 | 55,467,459 | 08/11/2025 Filed 2025-08-12 | SCHEDULE 13D/AAmendment 13 | Open filing 0001140361-25-030666 Dispute this row |
| Innoviva Strategic Opportunities LLC Common Stock, $0.01 par value | 70 | 46,756,659 | 08/11/2025 Filed 2025-08-12 | SCHEDULE 13D/AAmendment 13 | Open filing 0001140361-25-030666 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,225,847 filings read, dated 2004-06-14 to 2026-11-16: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 1 |
| 2016 | 204,322 |
| 2017 | 202,494 |
| 2018 | 202,048 |
| 2019 | 193,638 |
| 2020 | 144,184 |
| 2021 | 224,474 |
| 2022 | 143,589 |
| 2023 | 199,811 |
| 2024 | 209,823 |
| 2025 | 235,520 |
| 2026 | 260,165 |
Filings made before the SEC required XML are listed, not extracted.